A$ 5.11
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Excellent growth
About
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, develops theranostic therapy and imaging products for the treatment of cancer in children and adults. Its lead product includes SARTATE, a targeted theranostic radiopharmaceutical used for diagnosing, staging, and treating cancers that express somatostatin receptor 2. The company is also developing SAR-Bombesin, a pan cancer theranostic radiopharmaceutical...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers.
Target Price
The average target price of CU6.AX is 6.7 and suggests 46% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
